Search Results for “DASSM Online Test 🧞 DASSM Ausbildungsressourcen 🌜 DASSM Online Prüfungen ➖ Öffnen Sie die Webseite ➤ www.itzert.com ⮘ und suchen Sie nach kostenloser Download von ⇛ DASSM ⇚ 💰DASSM Testantworten”

Examples

Sino-Nasal Outcome Test 22 (SNOT-22)

Reduction in Sino-Nasal Outcome Test-22 (SNOT-22) Scores* View study design XHANCE trial design & details XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 … Continued

Retail Pharmacies

CoPay Savings Program Eligible, commercially insured patients with coverage for XHANCE pay as little as $0 using the XHANCE savings card* Get Savings CardGet Savings Card NOTICE OF RESTRICTION FOR … Continued

Terms of Use

BEFORE ACCESSING THIS WEBSITE, PLEASE READ THE FOLLOWING TERMS OF USE CAREFULLY AS THEY GOVERN YOUR USE OF THIS SITE. BY ACCESSING THIS SITE, YOU SIGNIFY YOUR AGREEMENT TO THESE … Continued

Privacy Policy

This Privacy Policy was last updated on October 12, 2017. BEFORE ACCESSING THIS WEBSITE, PLEASE READ THIS PRIVACY POLICY CAREFULLY. BY ACCESSING THIS SITE, YOU SIGNIFY YOUR AGREEMENT TO THIS … Continued

Resources

XHANCE resources for healthcare professionals Mechanism of Delivery and Polyp Reduction Journey Through the Nasal Anatomy Follow along as medication delivered by XHANCE travels through the nasal anatomy. The EDS® … Continued

FAQs

FREQUENTLY ASKED QUESTIONS ABOUT XHANCE XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older. If your patients have questions about … Continued

Administration

Administration information for XHANCE XHANCE is easy to use1 Please see Instructions for Use for detailed administration instructions. To prime XHANCE for first use: Remove the cap and shake the … Continued

Reduction in Bilateral Polyp Grade

Reduction in bilateral polyp grade Mean Change in Bilateral Polyp Grade Coprimary Endpoint – Week 161,2* Baseline grade: placebo EDS, 3.8; XHANCE 186 mcg BID, 3.9; XHANCE 372 mcg BID, … Continued

Dosing and Administration

Dosing and Administration XHANCE is easy to use1 Please see Instructions for Use for detailed administration instructions. Your browser doesn’t support HTML5 video tag.

+

References:

Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134.
Data on file. OptiNose US, Inc.

INDICATIONS

XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.

References:

Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134.
Data on file. OptiNose US, Inc.